Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 17 citing articles:

Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 27
An update on chronic complications of diabetes mellitus: from molecular mechanisms to therapeutic strategies with a focus on metabolic memory
Tongyue Yang, Qi Feng, Feng Guo, et al.
Molecular Medicine (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 9
COVID-19 promotes endothelial dysfunction and thrombogenicity: role of proinflammatory cytokines/SGLT2 prooxidant pathway
Ali Mroueh, W Fakih, Adrien Carmona, et al.
Journal of Thrombosis and Haemostasis (2023) Vol. 22, Iss. 1, pp. 286-299
Open Access | Times Cited: 16
Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation
Wenxin Sheng, Jianshu Yu, Hao Zhang, et al.
Molecular Immunology (2024) Vol. 167, pp. 43-52
Open Access | Times Cited: 6
Recent Advances in Promoting Bone Regeneration in Type 2 Diabetes Using Drug Delivery Vehicles and Vehicle‐Free Therapeutics
Yasamin Pesaran Afsharian, Mostafa Rahimnejad, Sayed Mahmood Rabiee, et al.
Advanced Therapeutics (2025)
Closed Access
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
Elena Y. Rykova, Vadim V. Klimontov, Elena Kazakova, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1670-1670
Open Access
Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease
Chaoyue Zhang, Yunke Shi, Changzhi Liu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
Hang‐Long Li, Yi-Kei Tse, Chanchal Chandramouli, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 12, pp. 3442-3451
Open Access | Times Cited: 19
Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies
Yasaman Naeimzadeh, Amir Tajbakhsh, Mahnaz Nemati, et al.
European Journal of Pharmacology (2024) Vol. 978, pp. 176803-176803
Closed Access | Times Cited: 3
Optimal control strategies for SGLT2 inhibitors as a novel anti-tumor agent and their effect on human breast cancer cells with the effect of time delay and hyperglycemia
Abeer Hamdan Alblowy, Normah Maan, Abdulkareem Afolabi Ibrahim
Computers in Biology and Medicine (2023) Vol. 166, pp. 107552-107552
Open Access | Times Cited: 7
GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway
Alessio Mazzieri, Giuseppe Basta, Riccardo Calafiore, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Unfavorable effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the skeletal system of nondiabetic rats
Piotr Londzin, Agata Brudnowska, Katarzyna Kurkowska, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 155, pp. 113679-113679
Open Access | Times Cited: 8
Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes
Bernhard K. Krämer, Sibylle J. Hauske, Robert Ćhilton, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 9, pp. 108588-108588
Open Access | Times Cited: 4
The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives—A Narrative Review
Giuseppe Miceli, Maria Grazia Basso, Andrea Roberta Pennacchio, et al.
Medicina (2024) Vol. 60, Iss. 11, pp. 1796-1796
Open Access
TorS ‐ Reframing a rational for type 2 diabetes treatment
Jacob Bar‐Tana
Diabetes/Metabolism Research and Reviews (2023) Vol. 40, Iss. 1
Open Access | Times Cited: 1
The changes of oxidative stress markers and vitamin E in patients with diabetes using SGLT2 inhibitors
Banu Büyükaydın
International journal of medical biochemistry/International journal of medical biochemistry : (2023), pp. 185-190
Open Access | Times Cited: 1
Targeting High Glucose-Induced Epigenetic Modifications at Cardiac Levels: The Role of SGLT2 and SGLT2 Inhibitors
Lucia Scisciola, Fatemeh Taktaz, Rosaria Anna Fontanella, et al.
Research Square (Research Square) (2022)
Open Access
Page 1

Scroll to top